Companies will develop saRNA therapies to treat neurological diseases
Category: Uncategorized
Cost-effectiveness estimates ‘uncertain’, according to NICE
Company has completed genetic analysis for UK and South African variants
Cabenuva consists of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine
Updated Date: Thu, 14 Jan 2021 00:00:00 EST
Updated Date: Thu, 14 Jan 2021 00:00:00 EST
Updated Date: Thu, 14 Jan 2021 00:00:00 EST
Updated Date: Thu, 14 Jan 2021 00:00:00 EST
Updated Date: Thu, 14 Jan 2021 00:00:00 EST
Researchers have published the first structural biology analysis of a section of the COVID-19 viral RNA called the […]